文献速递肝病消化道肿瘤与早癌

蛋白二硫键异构酶抑制协同增强索拉非尼对肝细胞癌的疗效

Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2017-07-20

本研究通过转录组分析与网络分析探讨索拉非尼在肝细胞癌中的作用及耐药机制,发现内质网应激网络中蛋白二硫键异构酶(PDI)抑制(PACMA 31)可在体外和体内协同增强索拉非尼疗效;PDI高表达的肝细胞癌患者对索拉非尼耐药且临床结局较差。

要点

  • 蛋白二硫键异构酶(PDI)抑制(PACMA 31)可协同增强索拉非尼在体外和体内的疗效。
  • PDI高表达的肝细胞癌患者对索拉非尼耐药且临床结局较差。
  • PDI是有望增强索拉非尼疗效的治疗靶点,也可作为预测索拉非尼反应的生物标志物。

核心结论

  • PDI是有望增强索拉非尼疗效的治疗靶点,也可作为预测索拉非尼反应的生物标志物。

研究设计与样本

  • 利用肝细胞癌细胞系对索拉非尼反应的mRNA变化进行转录组分析并结合网络分析,同时进行体外实验和小鼠异种移植模型实验。

主要发现

  • 基因列表功能富集分析和基因集富集分析显示,索拉非尼存在时蛋白毒性应激和凋亡模块被激活。
  • 内质网应激网络模型分析结合体外实验显示,口服活性PDI抑制剂(PACMA 31)引入额外应激可协同增强索拉非尼在体外和体内的疗效,并得到小鼠异种移植模型证实。
  • 与PDI低表达组相比,PDI高表达的肝细胞癌患者对索拉非尼耐药且临床结局较差。

临床怎么用

  • 作者认为PDI是有望增强索拉非尼疗效的治疗靶点,也可作为预测索拉非尼反应的生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Sorafenib is the only approved targeted drug for hepatocellular carcinoma (HCC), but its effect on patients' survival gain is limited and varies over a wide range depending on pathogenetic conditions. Thus, enhancing the efficacy of sorafenib and finding a reliable predictive biomarker are crucial to achieve efficient control of HCCs. In this study, we utilized a systems approach by combining transcriptome analysis of the mRNA changes in HCC cell lines in response to sorafenib with network analysis to investigate the action and resistance mechanism of sorafenib. Gene list functional enrichment analysis and gene set enrichment analysis revealed that proteotoxic stress and apoptosis modules are activated in the presence of sorafenib. Further analysis of the endoplasmic reticulum stress network model, combined with in vitro experiments, showed that introducing an additional stress by treating the orally active protein disulfide isomerase (PDI) inhibitor (PACMA 31) can synergistically increase the efficacy of sorafenib in vitro and in vivo, which was confirmed using a mouse xenograft model. We also found that HCC patients with high PDI expression show resistance to sorafenib and poor clinical outcomes, compared to the low-PDI-expression group. CONCLUSION: These results suggest that PDI is a promising therapeutic target for enhancing the efficacy of sorafenib and can also be a biomarker for predicting sorafenib responsiveness. (Hepatology 2017;66:855-868).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Won JK, Yu SJ, Hwang CY, et al. Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology. 2017. PMID: 28439950. doi:10.1002/hep.29237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。